Charles Schwab’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Sell |
486,601
-8,426
| -2% | -$288K | ﹤0.01% | 1895 |
|
|
2026
Q1 | $16.4M | Buy |
495,027
+47,745
| +11% | +$2.02M | ﹤0.01% | 1856 |
|
|
2025
Q4 | $20.7M | Buy |
447,282
+40,433
| +10% | +$1.69M | ﹤0.01% | 1725 |
|
|
2025
Q3 | $14.2M | Buy |
406,849
+20,749
| +5% | +$721K | ﹤0.01% | 1931 |
|
|
2025
Q2 | $11.4M | Buy |
386,100
+30,841
| +9% | +$880K | ﹤0.01% | 1949 |
|
|
2025
Q1 | $10.6M | Sell |
355,259
-12,147
| -3% | -$371K | ﹤0.01% | 1928 |
|
|
2024
Q4 | $10.5M | Sell |
367,406
-14,088
| -4% | -$466K | ﹤0.01% | 1992 |
|
|
2024
Q3 | $14.7M | Buy |
381,494
+16,655
| +5% | +$594K | ﹤0.01% | 1856 |
|
|
2024
Q2 | $11.7M | Buy |
364,839
+24,406
| +7% | +$846K | ﹤0.01% | 1963 |
|
|
2024
Q1 | $13.2M | Buy |
340,433
+34,967
| +11% | +$1.22M | ﹤0.01% | 1839 |
|
|
2023
Q4 | $9.4M | Sell |
305,466
-4,673
| -2% | -$117K | ﹤0.01% | 2016 |
|
|
2023
Q3 | $6.93M | Buy |
310,139
+14,667
| +5% | +$335K | ﹤0.01% | 2108 |
|
|
2023
Q2 | $6.35M | Buy |
295,472
+8,447
| +3% | +$192K | ﹤0.01% | 2130 |
|
|
2023
Q1 | $6.89M | Buy |
287,025
+33,484
| +13% | +$888K | ﹤0.01% | 2053 |
|
|
2022
Q4 | $5.88M | Buy |
253,541
+4,065
| +2% | +$82K | ﹤0.01% | 2135 |
|
|
2022
Q3 | $4M | Buy |
249,476
+6,947
| +3% | +$123K | ﹤0.01% | 2334 |
|
|
2022
Q2 | $4.3M | Sell |
242,529
-8,509
| -3% | -$143K | ﹤0.01% | 2249 |
|
|
2022
Q1 | $5.11M | Sell |
251,038
-14,092
| -5% | -$266K | ﹤0.01% | 2270 |
|
|
2021
Q4 | $4.95M | Sell |
265,130
-32,096
| -11% | -$626K | ﹤0.01% | 2360 |
|
|
2021
Q3 | $5.87M | Buy |
297,226
+1,771
| +0.6% | +$38.3K | ﹤0.01% | 2300 |
|
|
2021
Q2 | $6.99M | Buy |
295,455
+60,294
| +26% | +$1.39M | ﹤0.01% | 2189 |
|
|
2021
Q1 | $5.57M | Buy |
235,161
+8,022
| +4% | +$191K | ﹤0.01% | 2245 |
|
|
2020
Q4 | $4.55M | Buy |
227,139
+898
| +0.4% | +$17.5K | ﹤0.01% | 2265 |
|
|
2020
Q3 | $4.71M | Buy |
226,241
+140,286
| +163% | +$2.53M | ﹤0.01% | 2090 |
|
|
2020
Q2 | $1.5M | Buy |
85,955
+4,969
| +6% | +$97.3K | ﹤0.01% | 2512 |
|
|
2020
Q1 | $1.32M | Sell |
80,986
-60,448
| -43% | -$1.25M | ﹤0.01% | 2417 |
|
|
2019
Q4 | $2.91M | Sell |
141,434
-76,364
| -35% | -$1.27M | ﹤0.01% | 2291 |
|
|
2019
Q3 | $2.5M | Hold |
217,798
| – | – | ﹤0.01% | 2312 |
|
|
2019
Q2 | $2.87M | Buy |
217,798
+49,860
| +30% | +$667K | ﹤0.01% | 2232 |
|
|
2019
Q1 | $2.54M | Buy |
167,938
+2,530
| +2% | +$40.5K | ﹤0.01% | 2282 |
|
|
2018
Q4 | $2.84M | Sell |
165,408
-41,455
| -20% | -$709K | ﹤0.01% | 2186 |
|
|
2018
Q3 | $3.05M | Buy |
206,863
+51,489
| +33% | +$913K | ﹤0.01% | 2279 |
|
|
2018
Q2 | $3.71M | Buy |
155,374
+104,255
| +204% | +$2.56M | ﹤0.01% | 2149 |
|
|
2018
Q1 | $1.31M | Hold |
51,119
| – | – | ﹤0.01% | 2442 |
|
|
2017
Q4 | $944K | Buy |
51,119
+6,083
| +14% | +$87.1K | ﹤0.01% | 2523 |
|
|
2017
Q3 | $473K | Hold |
45,036
| – | – | ﹤0.01% | 2734 |
|
|
2017
Q2 | $564K | Hold |
45,036
| – | – | ﹤0.01% | 2645 |
|
|
2017
Q1 | $454K | Hold |
45,036
| – | – | ﹤0.01% | 2684 |
|
|
2016
Q4 | $702K | Buy |
45,036
+23,700
| +111% | +$394K | ﹤0.01% | 2542 |
|
|
2016
Q3 | $411K | Hold |
21,336
| – | – | ﹤0.01% | 2685 |
|
|
2016
Q2 | $253K | Buy |
+21,336
| New | +$352K | ﹤0.01% | 2851 |
|
|
2016
Q1 | – | Sell |
-8,736
| Closed | -$241K | – | 3063 |
|
|
2015
Q4 | $241K | Buy |
+8,736
| New | +$184K | ﹤0.01% | 2922 |
|
Other funds holding COLL
JT
EAM
Charles Schwab's COLL Position: Q2 2026 in Review
Charles Schwab reduced its Collegium Pharmaceutical (COLL) stake by 1.7% in Q2 2026, selling an estimated $288K and leaving 486,601 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1895.
Charles Schwab first reported a position in COLL in Q4 2015 and has held it in 42 quarters since. The position peaked at $20.7M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Charles Schwab held 486,601 shares of Collegium Pharmaceutical worth $17.6M as of Q2 2026.
- Charles Schwab sold 8,426 Collegium Pharmaceutical shares in Q2 2026, an estimated $288K.
- Collegium Pharmaceutical made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1895 holding.
- Charles Schwab first reported a position in Collegium Pharmaceutical in Q4 2015 and has held it in 42 quarters since.
- Charles Schwab's Collegium Pharmaceutical position peaked at $20.7M in Q4 2025.
- 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.